Banerjee Amitava, Pogge Thomas
Stroke Prevention Research Unit, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom.
Indian J Med Ethics. 2010 Oct-Dec;7(4):240-3. doi: 10.20529/IJME.2010.089.
Global health inequities persist despite significant increases in funding and a growing number of global health initiatives. Especially vulnerable to disease, the poor majority of the world's population currently cannot afford advanced medicines, and the diseases confined to the poor receive little attention from pharmaceutical research. As a complement to the existing intellectual property regime, we have proposed the Health Impact Fund (HIF) as a mechanism that would create incentives for the development and optimal promotion of new high-impact medicines sold at the cost of manufacture. In this article, we outline the HIF and its ethical significance.
尽管全球卫生资金大幅增加，全球卫生倡议的数量也不断增多，但全球卫生不平等现象依然存在。世界上大多数贫困人口特别容易患病，目前他们买不起先进药物，而那些穷人易患的疾病很少受到药物研究的关注。作为现有知识产权制度的补充，我们提议设立健康影响基金（HIF），作为一种机制，为开发和以制造成本推广新的高影响力药物创造激励措施。在本文中，我们概述了健康影响基金及其伦理意义。
